Bevacizumab, a monoclonal antibody (mAb) neutralizing VEGF, was tested in a preclinical model of CCA, in which it exerted an anti-angiogenic effect through the inhibition of both the peri- and intra-tumoral vascularization resulting in the reduction of tumor growth. The gene discussed is VEGFA; the disease is cholangiocarcinoma.